Straumann Holding AG (STMN) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Straumann Holding AG stock CHF 45.50, price CHF 105, that is 56.5% below the price, quality 68 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range CHF 74.97 – CHF 199.74 · fair‑value band CHF 28.95 – CHF 59.15 · the CHF 104.50 price screens above the CHF 45.50 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Straumann Holding in your weekly email
Every Wednesday you see whether Straumann Holding is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Straumann Holding AG provides tooth replacement and orthodontic solutions in Switzerland, the United States, China, Germany, Brazil, Japan, France, and internationally.
Show moreShow less
It operates through Sales Europe, Middle East and Africa; Sales North America; Sales Asia Pacific; Sales Latin America; and Operations segments.
The company offers dental implants, instruments, CADCAM prosthetics, orthodontic and clear aligners, biomaterials, and digital equipment and solutions for use in tooth correction, replacement, and restoration, as well as to prevent tooth loss.
It also provides implant systems, components, and related instruments, as well as healing components, materials and surfaces, surgical sets and instruments, and guided surgery and navigation products; prosthetics, including angled solutions, connections, components, and molar solutions; intra-oral and lab scanners, milling machines, dynamic navigation systems, and 3D printers; consumables, such as blocks, discs, resins, titanium bases, and abutment blanks, as well as scan bodies, analogs, and sleeves; online education; and dentists and dental labs solutions.
In addition, the company offers regenerative solutions for tooth preservation, implant-site management, and implant preservation; scanner hardware, software licenses, sterile-packaged products, customer training, and other products; and logistics and supply chain services.
Further, it provides thermoplastics; implant treatment referral; high-tech materials; artificial intelligence solutions for dental applications; and 3D orthodontic treatment animations.
The company sells its products under the Straumann, Neodent, Medentika, Anthogyr, ClearCorrect, NUVO, and other brands through a network of distribution subsidiaries and partners, and third-party distributors, as well as through its e-shop.
It serves clinicals needs, patient segments, and healthcare systems. Straumann Holding AG was founded in 1954 and is headquartered in Basel, Switzerland.
Stock analysis
Straumann Holding AG (STMN) currently trades at CHF 104.50, while our model-based Fair Value estimate is CHF 45.50, 56% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of CHF 46.53 per share, and 0 of the 26 models we run sit above the CHF 104.50 price.
Bear case: the Asset-Based group reads lowest at CHF 5.41, and 26 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: CHF 28.95 (bear) to CHF 59.15 (bull), the price of CHF 104.50 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 68/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Straumann Holding AG reported revenue of CHF 2.6B in FY2025 versus CHF 2.0B in FY2021, a compound +6.5%/yr. Reported net income was CHF 358M in FY2025, compounding −2.5%/yr from FY2021.
Key figures
Market cap CHF 16.7B Large · P/E ratio 45.2 · P/S ratio 6.33 · EPS (TTM) CHF 2.31 · Dividend yield 1.0% · Net margin 14.0% · Return on equity 17.1% · Return on assets (EBIT) 15.4% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 69 out of 100 (low confidence).
What moves the price
The share trades about 4% below its 52-week high and 39% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −44% fair-value upside, at −56%, STMN screens richer than that median.
Fair Value models
BearCHF 28.95Fair Value CHF 45.50BullCHF 59.15
Price CHF 104.50 · Downside -56.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (CHF 1.12 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.98/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+4.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.8%
Start year 2020 (pandemic). Over 10 years: +12.6% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+4.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+3.1%
Dividend (yield on the price)1.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.3.1% vs 8.4%, slowing
Profit margin 2019 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.25% → 21%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+27.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+8.1%
Yearly sales growth analysts expect, extended to five years.
After inflation (Switzerland: IMF forecast 0.6% a year to 2030, 0.8% from 2016 to 2025) that is about +26.6% a year for the price and +7.5% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (87 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
AI conclusion: Moderate positioning supports organic revenue growth and market share gains in implants and digital dentistry, yet thin public signals limit confirmation of a durable competitive moat.
Main risk: Cheaper implant makers such as Osstem Implant and MegaGen could capture share or force price reductions in value segments and emerging markets, hitting Straumann's premium pricing and margins.
Bull case: Straumann could leverage its digital ecosystem and artificial intelligence tools in AXS and coDiagnostiX to bind clinicians through superior workflows and efficiency gains that value rivals struggle to match.
Bear case: If value competitors and regulatory price pressure intensify, Straumann might lose share in faster-growing segments and see sustained margin compression across its implant and digital portfolio.
Straumann keeps delivering organic revenue growth above 7 percent in the first half and market share gains across regions while confirming an upgraded full-year profitability target. A new CEO steps in at year-end after years of steady execution in implants and digital dentistry. Does the leadership change keep the momentum going or risk a pause in a market where efficiency gains matter most?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 181 stocks
Beats the industry median on 5/15 measures
Overall it trails its industry peers.
Valuation
Quality Score68 · Top 25%
Fair Value upside−56.5% · Bottom 25%
Profitability
Return on equity (12 months)17.1% · Top 25%
Return on assets9.4% · Top 25%
Net margin (12 months)14.0% · Above median
Operating margin (12 months)25.1% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)2.3% · Below median
Dividend yield (12 months)1.0% · Below median
Balance sheet
Debt / equity0.12× · Above median
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Straumann Holding AG Fair Value". https://www.fairvalue-calculator.com/stock/STMN
Frequently asked questions
Is Straumann Holding AG (STMN) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of CHF 45.50 versus a price of CHF 104.50, about 56% lower (overvalued).
What is the fair value of STMN?
Our model-based fair value for Straumann Holding AG is CHF 45.50 (as of Nov 8, 2026), built from audited fundamentals. The current price: CHF 104.50.
What is the quality score of STMN?
Straumann Holding AG has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Straumann Holding AG (STMN)?
Our model-based price target is the fair value of CHF 45.50 (as of Nov 8, 2026) from 26 valuation models. Cautious scenario CHF 28.95, optimistic scenario CHF 59.15. It is a calculation from audited fundamentals, not an analyst target.
What is the Straumann Holding AG stock forecast for 2026?
Our models put fair value at CHF 45.50, about 56% lower versus a price of CHF 104.50 (overvalued). Cautious scenario CHF 28.95, optimistic scenario CHF 59.15. The calculation is refreshed regularly with new filings.
What is the revenue of Straumann Holding AG (STMN)?
Straumann Holding AG reported trailing-twelve-month revenue of about CHF 2.6B (latest available figure, as of Nov 8, 2026).
Does Straumann Holding AG pay a dividend?
Straumann Holding AG currently shows a dividend yield of 0.96% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Straumann Holding AG (STMN) and when is the ex-dividend date?
Straumann Holding AG pays a dividend of CHF 1.00 per share a year, a dividend yield of 1.0%. The last ex-dividend date was Apr 21, 2026. A dividend has been paid every year since at least 1999. The payout ratio is 43.3% of earnings. Free cash flow covers the dividend 2.07 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Straumann Holding AG (STMN)?
For today's price to be fair in a discounted-cash-flow model, Straumann Holding AG would have to grow free cash flow by +27.4 % per year for five years (discount rate 9.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +12.8 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of STMN use?
Our models discount Straumann Holding AG at 9.9 %: a base by market capitalisation (large), damped by beta 1.38, country premium for Switzerland. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Straumann Holding AG that is +27.4 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.9 %) and the same formula as our fair value.
How much growth has Straumann Holding AG (STMN) delivered so far?
Over the past 5 years revenue at Straumann Holding AG grew +12.8 % a year. The price currently implies free-cash-flow growth of +27.4 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Straumann Holding AG (STMN) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Straumann Holding AG (+27.4 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Straumann Holding AG (STMN)?
The free-cash-flow yield on the price is 1.98 %: that much free cash flow Straumann Holding AG produces per unit of market value. When it exceeds the discount rate of our models (9.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Straumann Holding AG (STMN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Straumann Holding AG it is CHF 45.50 per share (as of Nov 8, 2026), against a price of CHF 104.50. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Straumann Holding AG stock overvalued or undervalued in 2026?
As of Nov 8, 2026, STMN trades above its calculated fair value: price CHF 104.50, fair value CHF 45.50, a gap of about −56% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of STMN?
No. The price is what the market pays today (CHF 104.50); the fair value is what the company's own numbers justify (CHF 45.50). For Straumann Holding AG the two are CHF 59.00 per share apart. That gap is exactly why we show both numbers side by side.
How much is Straumann Holding AG worth?
The market values Straumann Holding AG at about CHF 16.7B (market capitalisation, as of Nov 8, 2026). Per share that is CHF 104.50; our models calculate a fair value of CHF 45.50 per share.
What do the bullish and bearish scenarios say about STMN?
Our models span a range for Straumann Holding AG: cautious scenario CHF 28.95, base CHF 45.50, optimistic CHF 59.15 per share (as of Nov 8, 2026, price CHF 104.50). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of STMN?
Straumann Holding AG trades at a price-to-earnings ratio of 45.2 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of CHF 45.50 is built from several models across several years. Other multiples: PEG 1.3, P/B 7.7, P/S 6.3, EV/EBITDA 21.9.
What is the PEG ratio of STMN?
The PEG ratio of Straumann Holding AG is 1.32 (P/E divided by earnings growth, as of Nov 8, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Straumann Holding AG (STMN)?
Balance-sheet figures for Straumann Holding AG (as of Nov 8, 2026): return on equity 17.1%, debt of 0.12 per unit of equity. They feed the Quality Score of 68/100, which measures business quality independently of the share price.
How far is STMN from its 52-week high?
Straumann Holding AG trades at CHF 104.50, about 4% below its 52-week high of CHF 108.60 and 39% above the low of CHF 74.97 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of CHF 45.50 is for.
Which stocks are comparable to Straumann Holding AG?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Straumann Holding AG stock attractive at the current price?
The data as of Nov 8, 2026: price CHF 104.50, calculated fair value CHF 45.50 (−56%), Quality Score 68/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of STMN calculated?
We run Straumann Holding AG through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of CHF 45.50 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Straumann Holding AG itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Straumann Holding AG (STMN)?
The closing price on Nov 6, 2026 was CHF 104.50. Our model-based fair value is CHF 45.50, about 56% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Straumann Holding AG right now?
The price sits above even our optimistic bull case (CHF 59.15). The favourable scenario is already priced in. Solid but not exceptional quality (68/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (CHF 28.95 to CHF 59.15) leaves room in how you read the outcome.
Where does the earnings growth of Straumann Holding AG (STMN) come from?
Earnings per share at Straumann Holding AG grew +8.8 % a year from 2014 to 2025. Broken into its drivers: revenue per share +13.2 %, EBIT margin −1.2 %, tax rate −2.4 %, residual (interest, one-offs) −0.4 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Straumann Holding AG
How large is the market capitalisation of Straumann Holding AG (STMN)?
The market capitalisation of Straumann Holding AG is CHF 16.7B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Straumann Holding AG (STMN)?
The price-to-sales ratio of Straumann Holding AG is 6.33 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Straumann Holding AG (STMN)?
Earnings per share at Straumann Holding AG are CHF 2.31 (price ÷ EPS = P/E 45.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Straumann Holding AG (STMN)?
The dividend yield of Straumann Holding AG is 1.0% (payout 43.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Straumann Holding AG (STMN)?
The net margin of Straumann Holding AG is 14.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Straumann Holding AG (STMN)?
The return on equity (ROE) of Straumann Holding AG is 17.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Straumann Holding AG (STMN)?
On an EBIT basis the return on assets of Straumann Holding AG is 15.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Straumann Holding AG (STMN)?
The operating margin of Straumann Holding AG is 25.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Straumann Holding AG (STMN)?
Revenue at Straumann Holding AG is growing +2.3% versus a year earlier (3y avg +3.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Straumann Holding AG (STMN)?
Earnings per share at Straumann Holding AG are growing +5.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Straumann Holding AG (STMN) carry?
The net debt of Straumann Holding AG is CHF 175M (fiscal year 2025, ≈ 0.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Straumann Holding AG in the live analysis
One click puts Straumann Holding AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 8, 2026